-------- Original Version -----------
Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint-------- English Version ------------
Tenax Therapeutics' Phase 3 trial of oral levosimendan in PH-HFpEF did not achieve its primary endpoint-------- Link if available ----------